Literature DB >> 6091102

Site-specific mutagenesis of the human fibroblast interferon gene.

D F Mark, S D Lu, A A Creasey, R Yamamoto, L S Lin.   

Abstract

Human fibroblast interferon has three cysteine residues, located at amino acid positions 17, 31, and 141. Using the technique of site-specific mutagenesis with a synthetic oligonucleotide primer, we changed the codon for cysteine-17 to a codon for serine. The resulting interferon, IFN-beta Ser-17, retains the antiviral, natural killer cell activation, and antiproliferative activities of native fibroblast interferon. The purified IFN-beta Ser-17 protein has an antiviral specific activity of 2 X 10(8) units/mg, similar to that of purified native fibroblast interferon. In addition, the purified protein is stable to long-term storage at -70 degrees C.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091102      PMCID: PMC391770          DOI: 10.1073/pnas.81.18.5662

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum ologodeoxyribonucleotide length.

Authors:  S Gillam; M Smith
Journal:  Gene       Date:  1979-12       Impact factor: 3.688

2.  Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: II. In vitro selection of mutant DNA.

Authors:  S Gillam; M Smith
Journal:  Gene       Date:  1979-12       Impact factor: 3.688

3.  Chemical synthesis and sequence studies of deoxyribooligonucleotides which constitute the duplex sequence of the lactose operator of Escherichia coli.

Authors:  K Itakura; N Katagiri; S A Narang; C P Bahl; K J Marians; R Wu
Journal:  J Biol Chem       Date:  1975-06-25       Impact factor: 5.157

4.  DNA restriction enzyme from E. coli.

Authors:  M Meselson; R Yuan
Journal:  Nature       Date:  1968-03-23       Impact factor: 49.962

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Synthesis of human fibroblast interferon by E. coli.

Authors:  D V Goeddel; H M Shepard; E Yelverton; D Leung; R Crea; A Sloma; S Pestka
Journal:  Nucleic Acids Res       Date:  1980-09-25       Impact factor: 16.971

7.  Expression of human fibroblast interferon gene in Escherichia coli.

Authors:  R Derynck; E Remaut; E Saman; P Stanssens; E De Clercq; J Content; W Fiers
Journal:  Nature       Date:  1980-09-18       Impact factor: 49.962

8.  The nucleotide sequence of human fibroblast interferon cDNA.

Authors:  T Taniguchi; S Ohno; Y Fujii-Kuriyama; M Muramatsu
Journal:  Gene       Date:  1980-06       Impact factor: 3.688

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  The isolation and amino acid/sugar composition of human fibroblastoid interferon.

Authors:  Y H Tan; F Barakat; W Berthold; H Smith-Johannsen; C Tan
Journal:  J Biol Chem       Date:  1979-08-25       Impact factor: 5.157

View more
  35 in total

1.  Expression of the Escherichia coli xylose isomerase gene in Saccharomyces cerevisiae.

Authors:  A V Sarthy; B L McConaughy; Z Lobo; J A Sundstrom; C E Furlong; B D Hall
Journal:  Appl Environ Microbiol       Date:  1987-09       Impact factor: 4.792

Review 2.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

Review 3.  Interferons: current status and future directions of this prototypic biological.

Authors:  R V Smalley; E C Borden
Journal:  Springer Semin Immunopathol       Date:  1986

4.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  A pilot study of recombinant interferon beta (IFN-beta ser) in patients with recurrent glioma.

Authors:  W K Yung; A M Castellanos; P Van Tassel; R P Moser; S G Marcus
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

6.  A novel concatenated dimer of recombinant bovine somatotropin.

Authors:  B N Violand; M Takano; D F Curran; L A Bentle
Journal:  J Protein Chem       Date:  1989-10

7.  Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor.

Authors:  W Y Weiser; P A Temple; J S Witek-Giannotti; H G Remold; S C Clark; J R David
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

8.  Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.

Authors:  J A Leon; M C Gutierrez; H Jiang; A Estabrook; S Waxman; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.

Authors:  G T Spear; D M Paulnock; R L Jordan; D M Meltzer; J A Merritt; E C Borden
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

10.  Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.

Authors:  Damiano Paolicelli; Vita Direnzo; Maria Trojano
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.